Celldex Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Celldex Therapeutics, Inc. (CLDX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $15.90 million as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2025-08-07
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $15.90M.
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $11.70M.
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $54.40M.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $82.50M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value |
|---|---|
| 2025-06-30 | $15.90M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $11.70M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $54.40M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $82.50M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $104.10M 10-Q · filed 2024-05-06 |
| 2023-09-30 | $41.20M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $68.60M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $78.10M 10-Q · filed 2023-05-04 |
| 2022-09-30 | $45.60M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $48.60M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $65.90M 10-Q · filed 2022-05-05 |
| 2021-09-30 | $140.60M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $69.90M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $31.60M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |